Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20 minutes long and presents 5-6 recently published articles from ADA journals.

Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting.

This issue will review:

1. Once-Weekly Insulin for Type 2 Diabetes
2. Impact of Bariatric Surgery on Microvascular Complications in Patients With Type 2 Diabetes
3. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
4. Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015
5. Sedentary Time and Metabolic Risk in Extremely Active Older Adults
6. Severe Hypoglycemia, Cardiac Structure and Function, and Risk of Cardiovascular Events Among Older Adults With Diabetes

For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

In this episode of Practice Pearls: Overcoming Therapeutic Inertia Drs. Robert Gabbay and Dr. Kamlesh Khunti discuss an overview of Therapeutic Inertia and the American Diabetes Associations initiative on overcoming therapeutic inertia. This is part of the American Diabetes Association’s Overcoming Therapeutic Inertia initiative supported by Strategic Sponsors AstraZeneca and Sanofi, plus Supporting Sponsors Merck and Novo Nordisk.

This episode is sponsored by the Overcoming Therapeutic Inertia  Initiative - for more information about resources for overcoming therapeutic inertia, just go to www.TherapeuticInertia.diabetes.org . 

Presented by:

Robert Gabbay, MD, PhD, FACP, Chief Scientific and Medical Officer, American Diabetes Association

Kamlesh Khunti, MD, PhD, Professor of Primary Care Diabetes & Vascular Medicine, University of Leicester, Leicester General Hospital, Leicester, UK

Neil Skolnik, M.D. , Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Associate Director, Family Medicine Residency Program, Abington Jefferson Health

In this third episode of the three-part series “Influenza and Diabetes,” Drs. John Russell and Neil Skolnik discuss frequently asked questions about diabetes, heart disease, the effects of influenza and the impact of influenza vaccination. They also discuss the details of currently available vaccine choices and strategies to enhance vaccination rates.  This special three-part series is supported by independent educational grant from Sanofi Pasteur.

For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

In this second episode of a three-part series on SGLT-2 inhibitors Drs. John Russell and Neil Skolnik discuss the renal effects of the SGLT-2 inhibitors, as well as the place of the SGLT-2is in the American Diabetes Association Guidelines and address practical issues about SGLT-2 inhibitor use.  In episode 1, Drs. Russell and Skolnik discussed an overview of the CVOTs for the SGLT-2 inhibitors and in episode 3 they will focus heart failure outcomes.  This special three-part series is supported by independent educational grant from AstraZeneca.

For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health